Bioasis Technologies

Bioasis Technologies EBITDA per Share

The EBITDA per Share of Bioasis Technologies (BIOAF) as of Oct 21, 2026 is -0.05 CAD. In the previous year, EBITDA per Share was 0.01 CAD — a change of -993.15% (lower).

EBITDA per Share

-0.05CAD

YoY

-993.15%

Last updated:

EBITDA per Share of Bioasis Technologies is 2022 -0.05 CAD. EBITDA per Share of Bioasis Technologies was 2021 0.01 CAD. It decreases by -993.15% lower compared to the previous year.

The Bioasis Technologies EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2015
-0.06 CAD
Jan 1, 2016
-0.06 CAD
Jan 1, 2017
-0.06 CAD
Jan 1, 2018
-0.10 CAD
Jan 1, 2019
-0.08 CAD
Jan 1, 2020
-0.07 CAD
Jan 1, 2021
0.01 CAD
Jan 1, 2022
-0.05 CAD
The Bioasis Technologies EBITDA per Share history
YEAREBITDA per ShareYoY
-0.05CAD-993.15%
0.01CAD-107.55%
-0.07CAD-12.63%
-0.08CAD-17.53%
-0.10CAD+58.69%
-0.06CAD+14.20%
-0.06CAD-12.81%
-0.06CAD-26.15%
-0.09CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioasis Technologies Stock analysis

What does Bioasis Technologies do? biOasis Technologies, Inc. generates revenue by developing therapeutics using its proprietary xB3 platform, which is designed to deliver treatments across the blood brain barrier for central nervous system disorders. The company focuses on areas of high unmet medical need, specifically targeting brain cancers and neurodegenerative diseases. This technology leverages a human transport protein found circulating at low levels in the blood to shuttle molecules to their targets within the brain via receptor-mediated transcytosis. The firm markets its in-house development programs aimed at creating both symptomatic and disease-modifying treatments for brain-related diseases and disorders. By utilizing the xB3 platform, biOasis Technologies, Inc. addresses specific therapeutic challenges in the central nervous system, offering solutions for conditions that currently lack adequate medical interventions. The business model relies on the efficacy of this delivery system to reach targets within the brain, serving the needs of patients suffering from these severe neurological conditions. Bioasis Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioasis Technologies stock

EBITDA per Share of Bioasis Technologies is -0.05 CAD in 2022.

EBITDA per Share of Bioasis Technologies changed from 0.01 CAD to -0.05 CAD, representing a -993.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Bioasis Technologies since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Bioasis Technologies

All Key Metrics — Bioasis Technologies